What is a podcast?
A podcast is an audio recording posted online — much like a radio show for your computer. It can be downloaded and listened to on your computer, iPod or any other device that plays MP3's. It can also be streamed via the web — so you can listen to it anywhere, at any time.

To learn more about podcasting and how to enjoy this exciting new feature of eMedical Dermatology Review, click here.

To listen to the Podcast, follow the links below.

Right-click to download the Edition here.

This saves the podcast directly on your computer's hard drive. There you can manage and play it like any song or audio file by using your music software (iTunes, Windows Media, Real Player, etc...) You can also transfer it to your iPod or MP3 player to listen to it on-the-go.

You can listen on the web here.

If you want to listen to the eMedical Dermatology Review Podcast right away, just click on the above link and it will open an internet browser and play the podcast for you via streaming media on the web. Please note: This podcast is a large file, so please be patient as the file downloads via the web. Once it's finished downloading, it will take a few more minutes for the toolbar to show. This could take a few minutes.

You can subscribe to the eMedical Dermatology Review Podcast here.

When you subscribe, you'll get new editions of the eMedical Dermatology Review Podcast automatically downloaded to your hard drive as soon as it becomes available. And just like the downloaded editions, you can manage and play it like any song or audio file by using your music software (iTunes, Windows Media, etc...) You can also transfer it to your iPod or MP3 player, Real Player, etc. to listen to it on-the-go.

CME/CNE/CPE INFORMATION        Accreditation Statement — back to top     This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.    Credit Designations — back to top     Physicians The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Nurses This 0.5 contact hour Educational Activity (Provider Directed/Learner Paced) is provided by The Institute for Johns Hopkins Nursing. Each podcast carries a maximum of 0.5 contact hours or a total of 7.0 contact hours for the six newsletters in this program. Pharmacists This program is approved for 0.5 hour credit (0.05 CEUs) for the podcast and is co-sponsored by the University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. A statement of CE credit will be mailed within 4 weeks of successful completion and evaluation of the program. ACPE Program #064-999-07-251-H01. Grievance Policy: A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.      Target Audience — back to top     This activity has been developed for the Dermatologist, PharmD, Nurses, Dermasurgeon, Dermatopathologist, Pediatric Dermatologist, Immunodermatologist, Wound Care Specialist.      Learning Objectives — back to top     The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing take responsibility for the content, quality, and the scientific integrity of this CE activity. At the conclusion of this activity, participants should be able to: Identify which biologic agents are considered safe to use in patients with chronic infectious disease conditions such as Hepatitis C and tuberculosis Discuss the appropriate use of biologics in patients with multiple sclerosis, lupus and/or malignancies Discuss the appropriate use of biologics in patients with congestive heart failure     Faculty Disclosure — back to top     It is the policy of The Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflict of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in each newsletter. Bernard A. Cohen, MD has indicated a past and current financial relationship with Novartis, Pharmaceuticals, Astellas Pharma Inc., Medicis and Connetics. He served on the Speaker's Bureau for Novartis, Pharmaceuticals, Astellas Pharma Inc., and Medicis. He has also received grants for studies from Novartis, Pharmaceuticals and Astellas Pharma Inc. and received support for a fellowship program from Connetics. Susan Matra Rabizadeh, MD, MBA has disclosed no relationships with commercial supporters. Mark Lebwohl, MD has disclosed that he has received grants for clinical research and educational activities from, has served as an advisor, consultant and speaker to, and has served as an investigator for Abbott, Amgen, Astellas, Centecor, Genentech and Novartis. Elizabeth Sloand, PhD, CRNP, has disclosed no relationships with commercial supporters.      Unlabeled/Unapproved Uses — back to top     Dr.Lebwohl has indicated that there will be references to unlabeled/unapproved uses of drugs or products in this presentation. Etanercept for hepatitis C is off-label; etanercept, adalimumab and infliximab are off-label for lupus     © 2007 JHUSOM, IJHN, UTCOP, and eMedicalDermatology Review Created by DKBmed.